8-K: Athira Pharma Reports Q2 2025 Results, Advances ALS Drug

Athira Pharma announced its second quarter 2025 financial results, highlighting positive Phase 1 data for ATH-1105 in ALS and ongoing strategic alternatives exploration.

Summary

• Athira Pharma reported financial results for the quarter ended June 30, 2025.
• Phase 1 clinical trial data for ATH-1105 in healthy volunteers demonstrated a favorable safety and tolerability profile, dose-proportional pharmacokinetics, and central nervous system (CNS) penetration, supporting continued clinical development.
• Preparation activities for a future ATH-1105 clinical trial in people living with ALS are substantially complete, contingent on the ongoing exploration of strategic alternatives.
• The company is exploring strategic alternatives focused on maximizing stockholder value, with Cantor Fitzgerald & Co. acting as an advisor.
• Further development of fosgonimeton (ATH-1017) has been paused following the September 2024 announcement that its LIFT-AD Phase 2/3 clinical trial did not meet its primary or key secondary endpoints.
• Cash, cash equivalents, and investments were $29.8 million as of June 30, 2025, a decrease from $51.3 million as of December 31, 2024.
• Net cash used in operations was $21.7 million for the six months ended June 30, 2025, a significant reduction from $48.1 million for the same period in 2024.
• Research and Development (R&D) expenses decreased to $3.7 million for Q2 2025 from $22.2 million for Q2 2024.
• General and Administrative (G&A) expenses decreased to $3.6 million for Q2 2025 from $5.9 million for Q2 2024.
• Net loss for Q2 2025 was $7.0 million, or $0.18 per share, compared to a net loss of $26.9 million, or $0.70 per share, for Q2 2024.

Sentiment

Score: 4

Explanation: While financial results show reduced burn and ATH-1105 Phase 1 data is positive, the failure of a late-stage drug (Fosgonimeton) and the ongoing strategic review create significant uncertainty and reflect a major setback for the company's primary pipeline. The positive financial metrics are largely a result of cost-cutting following this setback.

Positives

• ATH-1105 Phase 1 trial showed a favorable safety profile and was well tolerated in healthy volunteers.
• ATH-1105 demonstrated dose-proportional pharmacokinetics and central nervous system (CNS) penetration, supporting its continued clinical development.
• Preclinical evidence for ATH-1105 indicates statistically significant improvements in nerve and motor function, biomarkers of inflammation and neurodegeneration, and survival in various ALS models.
• Substantial completion of preparation activities for a future ATH-1105 clinical trial in ALS patients.
• Significant reduction in Research and Development (R&D) expenses to $3.7 million in Q2 2025 from $22.2 million in Q2 2024.
• Reduction in General and Administrative (G&A) expenses to $3.6 million in Q2 2025 from $5.9 million in Q2 2024.
• Net loss significantly decreased to $7.0 million ($0.18 per share) in Q2 2025 from $26.9 million ($0.70 per share) in Q2 2024.
• Net cash used in operations for the six months ended June 30, 2025, was $21.7 million, a substantial decrease from $48.1 million for the same period in 2024.

Negatives

• Fosgonimeton (ATH-1017) Phase 2/3 LIFT-AD clinical trial failed to meet its primary or key secondary endpoints in September 2024.
• Further development of fosgonimeton, including its open-label extension trial, has been paused.
• Cash, cash equivalents, and investments decreased to $29.8 million as of June 30, 2025, from $51.3 million as of December 31, 2024, indicating continued cash burn.
• The company is exploring strategic alternatives, which often signals significant challenges or a need for restructuring following clinical setbacks.

Risks

• Data from preclinical and clinical trials may not support the safety, efficacy, and tolerability of drug candidates.
• Development of drug candidates may cease or be delayed.
• Regulatory authorities could object to protocols, amendments, and other submissions.
• Future potential regulatory milestones for drug candidates may be insufficient to support regulatory submissions or approval.
• Trials may not be sufficiently powered to meet planned endpoints.
• Inability to recruit sufficient patients for clinical trials.
• Outcome of legal proceedings that may in the future be instituted against Athira, its directors, and officers.
• Possible negative interactions of drug candidates with other treatments.
• FDA regulatory delays and uncertainty, including new policies, changes in leadership of federal agencies, staff layoffs, budget cuts to agency programs and research, and changes in drug pricing controls.
• Assumptions regarding financial condition and the sufficiency of cash, cash equivalents, and investments to fund planned operations may be incorrect.
• Adverse conditions in the general domestic and global economic markets, including as a result of tariffs.
• Impact of competition.
• Impact of drug candidate development and clinical activities on operating expenses.
• Impact of new or changing laws and regulations.
• Risks related to the exploration of strategic alternatives.

Future Outlook

The company plans to provide an update regarding its future plans for ATH-1105 development in the near future. It intends to initiate a future clinical trial for ATH-1105 in people living with ALS, either independently or in conjunction with a partner, subject to the ongoing exploration of strategic alternatives focused on maximizing stockholder value.

Management Comments

• Mark Litton, Ph.D., President and Chief Executive Officer: "We are pleased with the progress we made in the first half of 2025 advancing ATH-1105 as a potential therapy for ALS."
• Mark Litton, Ph.D., President and Chief Executive Officer: "In May, we announced encouraging first-in-human safety and pharmacokinetic data from our Phase 1 clinical trial of ATH-1105 at the Annual ALS Drug Development Summit. The data presented showed favorable safety and tolerability in healthy volunteers and dose proportional pharmacokinetics and CNS penetration, which support ATH-1105s continued development."
• Mark Litton, Ph.D., President and Chief Executive Officer: "We have substantially completed preparation activities to enable initiation of a future clinical trial in people living with ALS by us or in conjunction with a partner subject to our continued exploration of strategic alternatives focused on maximizing stockholder value. We look forward to providing an update regarding our plans in the near future."

Industry Context

The biopharmaceutical industry, particularly in neurodegenerative diseases, is characterized by high research and development costs and significant clinical trial risks. Athira's experience with the failure of its late-stage Fosgonimeton program is common in this high-risk sector. The company's pivot to focus on ATH-1105 for ALS and the exploration of strategic alternatives reflect a typical response by biotech firms to clinical setbacks, aiming to preserve capital and focus on the most promising assets. The emphasis on the neurotrophic HGF system represents a specific, targeted approach within the broader neurodegeneration therapeutic landscape.

Comparison to Industry Standards

• No direct comparisons to specific comparable companies, projects, or results within the industry were provided in the filing.

Stakeholder Impact

• Shareholders: Significant impact due to the failure of a key late-stage drug candidate (Fosgonimeton), the ongoing strategic review (which could lead to various outcomes including sale, merger, or further dilution), and continued cash burn. The positive early data for ATH-1105 offers some future potential.
• Employees: Potential impact from cost-cutting measures and the strategic review, which could lead to restructuring or layoffs.
• Patients (ALS): Potential future benefit from ATH-1105 if clinical trials are successful and the drug reaches market.
• Patients (Alzheimer's): Disappointment due to the discontinuation of Fosgonimeton development.

Next Steps

• Provide an update regarding plans for ATH-1105 development in the near future.
• Initiate a future clinical trial for ATH-1105 in people living with ALS, either independently or in conjunction with a partner, subject to strategic alternatives exploration.
• Continue exploration of strategic alternatives focused on maximizing stockholder value.

Key Dates

Recommendation

The company faces significant challenges with the failure of a late-stage asset (Fosgonimeton) and is undergoing a strategic review, which introduces substantial uncertainty. However, the positive early-stage data for ATH-1105 and the significant reduction in cash burn offer a glimmer of hope. A 'hold' recommendation allows investors to await clarity on the outcome of the strategic alternatives process and further development plans for ATH-1105 before making a more definitive investment decision.

Keywords

Athira Pharma, ATHA, biopharmaceutical, neurodegeneration, ALS, Alzheimer's disease, Parkinson's disease, ATH-1105, Fosgonimeton, ATH-1017, clinical trial, Phase 1, HGF system, financial results, Q2 2025, strategic alternatives, drug development